NASDAQ:BCYC Bicycle Therapeutics Q2 2025 Earnings Report $8.09 -0.08 (-0.98%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Bicycle Therapeutics EPS ResultsActual EPS-$1.14Consensus EPS -$0.95Beat/MissMissed by -$0.19One Year Ago EPSN/ABicycle Therapeutics Revenue ResultsActual Revenue$2.90 millionExpected Revenue$9.43 millionBeat/MissMissed by -$6.53 millionYoY Revenue GrowthN/ABicycle Therapeutics Announcement DetailsQuarterQ2 2025Date8/8/2025TimeBefore Market OpensConference Call DateFriday, August 8, 2025Conference Call Time7:00AM ETUpcoming EarningsBicycle Therapeutics' Q3 2025 earnings is scheduled for Thursday, October 30, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bicycle Therapeutics Earnings HeadlinesWeiss Ratings Reaffirms Sell (D-) Rating for Bicycle Therapeutics (NASDAQ:BCYC)October 16, 2025 | americanbankingnews.comBicycle Therapeutics: Looking For Their Niche, Addressing Cash BurnOctober 15, 2025 | seekingalpha.comThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted Cruz calling the White House a “mafia,” and even Trump’s approval rating slipping. But veteran analyst Porter Stansberry says this isn’t really about politics at all. It’s part of a much larger shift he calls The Final Displacement — a historic economic and social realignment already impacting millions of Americans. His new documentary explains what’s driving it and how to prepare before it accelerates further.October 20 at 2:00 AM | Porter & Company (Ad)Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 12, 2025 | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) has caught the attention of institutional investors who hold a sizeable 45% stakeSeptember 12, 2025 | finance.yahoo.comBicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comSee More Bicycle Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicycle Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicycle Therapeutics and other key companies, straight to your email. Email Address About Bicycle TherapeuticsBicycle Therapeutics (NASDAQ:BCYC) plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology. Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Its oncology portfolio includes targeted agents aimed at tumor-associated receptors and tumor-penetrating ligands designed to deliver therapeutic payloads. In parallel, the company is advancing candidates in neuroscience and immuno-oncology, seeking to address high-unmet-need conditions. Bicycle’s programs are being evaluated in preclinical and early clinical studies, and the company has established research collaborations with several global biopharmaceutical organizations to accelerate the clinical development of its lead molecules. Headquartered in Cambridge, UK, Bicycle Therapeutics has expanded its presence with operations in the United States to support its growing clinical activities and partnerships. The company is led by an experienced management team with deep expertise in peptide chemistry, translational research and drug development. By integrating its proprietary platform with strategic alliances, Bicycle Therapeutics aims to advance a new class of precision medicines capable of reaching challenging therapeutic targets with improved safety and efficacy profiles.View Bicycle Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025)Danaher (10/21/2025)Elevance Health (10/21/2025)GE Aerospace (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
